A Study Utilising Data From European Union (EU) National Multiple Sclerosis (MS) Registries to Assess the Incidence of Anti-Natalizumab Antibody Among Participants Who Receive Subcutaneous Administration of Natalizumab for Treatment of Relapsing-remitting Multiple Sclerosis (RRMS)
Condition:   Multiple Sclerosis Intervention:   Drug: Natalizumab Sponsor:   Biogen Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 29, 2023 Category: Research Source Type: clinical trials

Czech Pharmaco-epidemiological Study on Disease Modifying Drugs
Condition:   Multiple Sclerosis Intervention:   Drug: interferons, glatiramer acetate, teriflunomide, dimethyl fumarate, alemtuzumab, cladribine, fingolimod, ponesimod, rituximab, ocrelizumab, ofatumumab, natalizumab Sponsor:   IMPULS Endowment Fund Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 9, 2023 Category: Research Source Type: clinical trials